Ernexa Therapeutics Inc. (ERNA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 8M 16M 24M Q4 '17: 21.3M Q1 '18: 21.8M Q2 '18: 21.9M Q3 '18: 22.7M Q4 '18: 23.3M Q1 '19: 22.4M Q2 '19: 22M Q3 '19: 20.6M Q4 '19: 19.8M Q1 '20: 17.4M Q2 '20: 12.9M Q3 '20: 9.8M Q4 '20: 5.8M Q2 '23: 0 Q3 '23: 51K Q4 '23: 68K Q1 '24: 115K Q2 '24: 162K Q3 '24: 598K Q4 '24: 582K Q1 '18 Q4 '18 Q3 '19 Q2 '20 Q2 '23 Q1 '24 Q4 '24

Gross Profit TTM

-200K 0 200K 400K 600K Q2 '23: -50K Q3 '23: -119K Q4 '23: -168K Q1 '24: -132K Q2 '24: -180K Q3 '24: 436K Q4 '24: 486K Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24

Operating Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -107.4M Q4 '21: -113.7M Q1 '22: -111.1M Q2 '22: -115M Q3 '22: -37M Q4 '22: -33.2M Q1 '23: -32.2M Q2 '23: -22.9M Q3 '23: -20.1M Q4 '23: -21.1M Q1 '24: -21.6M Q2 '24: -22M Q3 '24: -18.7M Q4 '24: -15.7M Q1 '25: -12.6M Q2 '25: -10.2M Q3 '25: -9.9M Q4 '25: -9.3M Q1 '26: -12.2M Q2 '26: -13.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '21: -116.8M Q4 '21: -122.5M Q1 '22: -113.4M Q2 '22: -106.7M Q3 '22: -28M Q4 '22: -24.6M Q1 '23: -20.6M Q2 '23: -21.7M Q3 '23: -20M Q4 '23: -21.7M Q1 '24: -22.9M Q2 '24: -23.9M Q3 '24: -44.9M Q4 '24: -44.5M Q1 '25: -46.1M Q2 '25: -43.7M Q3 '25: -18.3M Q4 '25: -14.1M Q1 '26: -11.4M Q2 '26: -12.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 150K 300K 450K Q2 '23: 50K Q3 '23: 170K Q4 '23: 236K Q1 '24: 247K Q2 '24: 342K Q3 '24: 162K Q4 '24: 96K Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24

Operating Cash Flow TTM

-27M -18M -9M 0 9M 18M 27M Q3 '21: -18.3M Q4 '21: -23.5M Q1 '22: -25.5M Q2 '22: -22.7M Q3 '22: -22.4M Q4 '22: -21M Q1 '23: -21.6M Q2 '23: -21.5M Q3 '23: -21.2M Q4 '23: -20.4M Q1 '24: -18.1M Q2 '24: -16.5M Q3 '24: -17M Q4 '24: -15.8M Q1 '25: -14.2M Q2 '25: -14.4M Q3 '25: -9.4M Q4 '25: -7M Q1 '26: -7.2M Q2 '26: -8.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-27M -18M -9M 0 9M 18M 27M Q1 '20: -550 Q2 '20: -2.7M Q3 '20: -5.5M Q4 '20: -8.1M Q1 '21: -9.7M Q2 '21: -14.3M Q3 '21: -18.3M Q4 '21: -23.6M Q1 '22: -25.7M Q2 '22: -23.1M Q3 '22: -22.8M Q4 '22: -21.3M Q1 '23: -21.8M Q2 '23: -21.5M Q3 '23: -21.2M Q4 '23: -20.4M Q1 '24: -18.2M Q2 '24: -16.9M Q3 '24: -17.3M Q4 '24: -16.2M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '20: 17.5M Q2 '20: 17.6M Q3 '20: 17.6M Q1 '21: 27.8K Q2 '21: 42.4M Q3 '21: 2.5M Q1 '22: 2.7M Q2 '22: 2.9M Q3 '22: 2.9M Q1 '23: 5.1M Q2 '23: 5.3M Q3 '23: 5.4M Q1 '24: 5.4M Q2 '24: 361K Q3 '24: 361K Q1 '25: 142K Q2 '25: 207K Q3 '25: 8.2M Q1 '26: 792K Q2 '26: 1.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-120.00 -80.00 -40.00 0.00 40.00 80.00 120.00 Q4 '19: -0.71 Q1 '20: -0.66 Q2 '20: -0.75 Q3 '20: -0.74 Q4 '20: -0.41 Q1 '22: -37.59 Q2 '22: -38.51 Q3 '22: -6.97 Q4 '22: -8.17 Q1 '23: -5.73 Q2 '23: -5.42 Q3 '23: -3.96 Q4 '23: -4.08 Q1 '24: -4.25 Q2 '24: -18.74 Q3 '24: -91.41 Q4 '24: -48.96 Q1 '25: -105.49 Q2 '25: -105.34 Q3 '25: -31.79 Q1 '20 Q4 '20 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.